Novavax on Thursday swung to a first-quarter profit from a year-ago loss, helped by reduced costs related to the development and sale of its COVID-19 vaccines, its only product on the market.

Yes, according to leading vaccine physician Paul Offit, who denounced the new placebo-controlled trial requirements for ...

On a per-share basis, the Gaithersburg, Maryland-based company said it had net income of $2.93. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine is sowing uncertainty about other ...

Senior leaders at the US Food and Drug Administration began pushing Moderna Inc. and Pfizer Inc. to file for full, formal ...

A blanket requirement for placebo-controlled trials threatens research ethics and vaccine access, it’s being argued.

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

The U.S. Food and Drug Administration said on Wednesday it will hold a meeting of experts on May 22 to discuss COVID-19 ...

Based on this transfer of rights, we do not expect Novavax to record product sales from its COVID-19 vaccine. We expect the company to provide an update on the technology transfer (related to its ...

The FDA has already delayed the approval of Novavax’s updated Covid vaccine, requiring the company to carry out a new ...

Robert F. Kennedy Jr., who oversees the FDA, intends to set new regulatory standards vaccine manufacturers couldn’t possibly ...

Novavax is recognized for its expertise in vaccine science, focusing on protein-based nanoparticles and adjuvants. The company’s growth strategy revolves around diversifying partnerships by out ...